Adrian Apetri

TL;DR: The results represent a proof of concept for the design of HA stem mimics that elicit bnAbs against influenza A group 1 viruses and completely protects mice in lethal heterologous and heterosubtypic challenge models, and reduces fever after sublethal challenge in cynomolgus monkeys.

TL;DR: The results suggest the presence of an ongoing antigen-driven immune response against tau in healthy individuals, and suggests that the human immune repertoire may contain antibodies that can serve as biomarkers or be exploited for therapy.

TL;DR: The studies reveal distinct changes in the local conformational dynamics of HA associated to the molecular mechanism of neutralization, establishing a marker for broad anti-HA activity and highlighting the potential for HDX-MS epitope mapping-based screening to identify promising candidates against HA at early stages of drug discovery.

TL;DR: The results suggest that the memory B-cell repertoire of PD patients might represent a potential source of biomarkers and therapies and differential reactivities were observed for all three human anti-α-synuclein antibodies across tissue treatment conditions by immunohistochemistry.

TL;DR: The development of an in vitro aggregation assay that mimics the expected steps associated with tau misfolding and aggregation in vivo is described and is a robust tool for screening drugs that could interfere with the pathogenesis of tau.